In addition, a reduced dose of ruxolitinib (5 mg BID) is recommended when patients have severe cytopenia, thrombocytopenia, neutropenia, or elevated total bilirubin, or when administered with strong CYP3A4 inhibitors [12, 13]. Here, CYP3A4 is linked to Decreased total neutrophil count.